pre-IPO PHARMA

COMPANY OVERVIEW

Gemini Therapeutics is a product engine company focused on redefining AMD and linked disorders with precision medicine. Our ocular therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our multimodal product engine has generated a rich pipeline including monoclonal antibodies, recombinant proteins and gene therapies.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Ophthalmology

  • WEBSITE

    https://www.geminitherapeutics.com


    CAREER WEBSITE

    https://www.geminitherapeutics.com/careers/


    SOCIAL MEDIA


    INVESTORS

    atlas-venture lightstone-ventures orbimed


    PRESS RELEASES


    Feb 8, 2021

    Gemini Therapeutics Debuts as Publicly Traded Precision Medicine Company Focused on Age-Related Macular Degeneration


    Feb 1, 2021

    Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy


    Jan 7, 2021

    Gemini Therapeutics Announces FDA Fast Track Designation Granted for GEM103 for the Treatment of Dry Age-Related Macular Degeneration (AMD) in Patients With Complement Factor H (CFH) Loss of Function Gene Variants


    Dec 16, 2020

    Genosity Enters Into an Agreement With Gemini Therapeutics to Develop a Diagnostic and Implement Testing to Support Gemini’s Age-Related Macular Degeneration Trial


    Nov 13, 2020

    Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Study


    For More Press Releases


    Google Analytics Alternative